Androgen receptor in triple negative breast cancer
Authors:
- K.M. McNamaraKMK.M. McNamara
- T. YodaTYT. Yoda
- K. TakagiKTK. Takagi
- Y. MikiYMY. Miki
- T. SuzukiTST. Suzuki
- H. SasanoHSH. Sasano
- 1 January 2013
- journal article
- review article
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 133, 66-76
Abstract
No abstract availableKeywords
This publication has 136 references indexed in Scilit:
- Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer NetworkCancer, 2012
- Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survivalBreast Cancer Research and Treatment, 2011
- Relative contributions of BRCA1 and BRCA2 mutations to “triple-negative” breast cancer in Ashkenazi WomenBreast Cancer Research and Treatment, 2011
- Reproductive history and risk of three breast cancer subtypes defined by three biomarkersCancer Causes & Control, 2010
- African ancestry and higher prevalence of triple‐negative breast cancerCancer, 2010
- Mammalian cell transfection: the present and the futureAnalytical and Bioanalytical Chemistry, 2010
- Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotypeCancer, 2007
- Prognostic markers in triple‐negative breast cancerCancer, 2006
- A collection of breast cancer cell lines for the study of functionally distinct cancer subtypesCancer Cell, 2006
- Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factorsThe Journal of Pathology, 1993